Stix Review: Who Should (and Should Not) Use This Brand

Is Stix a Legitimate Company?

Stix is a real, operating direct-to-consumer brand focused on reproductive wellness diagnostics. It sells physical products, primarily home tests, through its website and third-party retailers. The company is not a pharmacy, does not employ licensed prescribers, and does not offer telehealth consultations.

Legitimacy in the OTC product space means something narrower than in the telehealth space. A brand can be "legit" in the sense that it ships real products that are what they claim to be, while still being the wrong choice for a specific woman's situation.

What FDA Clearance Actually Means for Home Tests

When a home test is marketed as FDA-cleared, it means the manufacturer submitted data showing the test performs at least as well as a predicate device already on the market. It does not mean the FDA independently tested that specific product in a real-world population. For pregnancy tests, the FDA's OTC clearance process requires sensitivity and specificity data, but brand-specific post-market performance studies are rarely published in peer-reviewed journals.

The clinical standard for human chorionic gonadotropin (hCG) detection in early pregnancy is a sensitivity of 20 mIU/mL or lower. Research published in the journal Clinical Chemistry found that among 18 OTC pregnancy test brands tested, only one reliably detected hCG at 20 mIU/mL. Stix was not among the brands evaluated in that 2011 study, and no equivalent independent comparative study for Stix products appears in PubMed as of the writing of this article.

LegitScript and Pharmacy Verification

LegitScript maintains a database of verified online pharmacies and telehealth companies. Because Stix does not dispense prescription medications, it falls outside the scope of LegitScript's pharmacy verification program. The absence of a LegitScript seal is neither a red flag nor an endorsement for a brand that sells only OTC diagnostics.

Specific Patient Profiles Who Should Avoid Relying on Stix

This is the section that matters most. Stix is not a clinical service, and for several specific groups of women, using it as a substitute for clinical evaluation carries real risk.

Women with Recurrent UTIs

Stix sells a home UTI test strip. These strips detect nitrites and leukocyte esterase in urine, the same markers used in point-of-care dipstick tests in clinical settings. The problem is specificity. A 2019 systematic review in the BMJ found that urine dipstick tests have a sensitivity of approximately 75% and a specificity of around 82% for UTI diagnosis, meaning roughly one in four true UTIs may be missed and roughly one in five positive results may be false positives.

For a woman with her first uncomplicated UTI, a positive home test combined with classic symptoms is a reasonable starting point for a telehealth consultation or urgent care visit. For a woman with two or more UTIs in six months, or three or more in a year, ACOG defines recurrent UTI as a distinct clinical entity requiring urine culture, sensitivity testing, and evaluation for underlying anatomical or hormonal factors. A dipstick cannot identify the causative organism or its antibiotic sensitivities. Using a Stix UTI test to self-manage recurrent infections delays the cultures and clinical workup that actually change outcomes.

Perimenopausal and postmenopausal women face an additional complication. Genitourinary syndrome of menopause (GSM) causes changes in vaginal and urethral epithelium that increase UTI risk and can produce symptoms that mimic UTI, including urgency and dysuria, without an active infection. The Menopause Society's 2023 position statement on GSM notes that estrogen deficiency significantly alters urinary tract defense mechanisms. A dipstick test cannot differentiate between a true UTI and GSM-related symptoms. These women need a clinician, not a home test strip.

Women with PCOS Trying to Conceive

Stix sells LH-based ovulation predictor kits (OPKs). For most ovulatory women, a surge in luteinizing hormone reliably predicts ovulation 24 to 36 hours in advance. Women with polycystic ovary syndrome have a different hormonal pattern. Research in Fertility and Sterility has documented that women with PCOS frequently show multiple LH surges per cycle or chronically elevated baseline LH, causing OPKs to produce false positives or to detect a hormone peak that does not correspond to actual follicle release.

ASRM's evidence-based guidelines on PCOS recommend transvaginal ultrasound monitoring and serum hormone testing as the standard approach to cycle monitoring in women with PCOS who are trying to conceive. An OPK purchased from Stix cannot replace a monitored cycle. Using one as the sole timing tool in PCOS may actually reduce the chance of timed intercourse coinciding with true ovulation.

Women with a History of Ectopic Pregnancy or Early Pregnancy Loss

A positive pregnancy test from any brand, including Stix, requires prompt clinical follow-up for any woman with a prior ectopic pregnancy. Home hCG tests confirm the presence of hCG but cannot localize the pregnancy or quantify the rise in hCG over 48 hours, the serial measurement clinicians use to distinguish a normally progressing intrauterine pregnancy from an ectopic or failing pregnancy. ACOG Practice Bulletin No. 193 on ectopic pregnancy recommends serum quantitative hCG in any woman at elevated risk. A positive Stix test should prompt a call to a clinician the same day, not a wait-and-see approach.

Perimenopausal Women Interpreting Cycle-Based Tests

OPKs and some pregnancy tests behave differently in perimenopause. LH rises naturally as ovarian reserve declines, meaning OPK readings in perimenopause are frequently positive without an impending ovulation. FSH-based menopause tests sold by brands like Stix detect a single elevated FSH value. The Menopause Society's guidance on menopause diagnosis is explicit: a single hormone test cannot diagnose menopause or rule out remaining fertility. A 50-year-old woman with irregular cycles who uses a Stix FSH test and receives a "positive" menopause indicator may incorrectly assume she no longer needs contraception. That assumption has resulted in unintended pregnancies. Perimenopause requires clinical evaluation, not a one-time home test.

What Stix Does Well (and Where It Fits)

Honest assessment requires acknowledging where the product category is genuinely useful. Home diagnostics are a legitimate tool for healthy, ovulatory women with regular cycles and no complex reproductive history.

Pregnancy Testing for Low-Risk Scenarios

For a woman with regular cycles who had unprotected sex, wants a discreet and convenient pregnancy test, and has no history of ectopic pregnancy or recurrent loss, a Stix pregnancy test is clinically equivalent to any other FDA-cleared OTC test. The primary considerations are cost, convenience, and when in the cycle the test is taken.

Testing before a missed period increases the false-negative rate substantially. A 2018 paper in AJOG notes that hCG doubles approximately every 48 hours in early pregnancy, meaning that at 10 days post-ovulation, many women have not yet reached the threshold for reliable detection. A negative result before a missed period does not rule out pregnancy.

Cycle Tracking Support for Ovulatory Women

Women with documented regular cycles, no fertility diagnosis, and no PCOS who are simply trying to time intercourse may find LH-based OPKs from any brand, including Stix, a reasonable starting point. The caveat is that OPKs confirm an LH surge, not confirmed ovulation. Some women have LH surges without releasing a follicle, a phenomenon called luteinized unruptured follicle syndrome. This is uncommon but not rare in women on NSAIDs or with certain hormonal profiles.

Stix Complaints: What Women Actually Report

No large-scale independent review database exists specifically for Stix product accuracy. The Better Business Bureau profile for Stix shows the company is not BBB-accredited as of early 2025, and the volume of complaints on that platform is low enough that no statistically meaningful pattern can be drawn. Third-party review aggregators show a mix of positive and negative feedback, with common complaints centering on:

• Test line faintness making interpretation difficult
• Customer service response times for returns or subscription management
• Shipping delays affecting time-sensitive testing needs

None of these complaints rise to the level of a safety concern or suggest product fraud. The more clinically meaningful concern is not whether Stix ships real products (it does) but whether women are using those products in place of clinical evaluation they actually need.

The FDA's MedWatch database is the appropriate channel for reporting a test that produced a result inconsistent with clinical confirmation. MedWatch reports for medical devices are searchable by product category, though individual brand complaint volumes for small OTC diagnostics companies are typically not publicly broken out.

Pregnancy and Lactation Considerations

Stix sells diagnostic tests, not drugs, so there is no teratogenicity risk from the products themselves. The relevant pregnancy and lactation considerations are about how home tests interact with care-seeking behavior during pregnancy.

Pregnancy

A positive home pregnancy test of any brand should be followed by confirmation with a clinician, particularly to:

1. Confirm intrauterine location in women with any risk factors for ectopic pregnancy (prior ectopic, prior pelvic inflammatory disease, tubal surgery, IUD use at time of conception).
2. Establish gestational dating with ultrasound, because home tests cannot date a pregnancy.
3. Begin prenatal care, including folic acid supplementation, which the CDC recommends at 400 mcg daily starting before conception and continuing through the first trimester.

The Stix website does not substitute for obstetric care. A positive test is the beginning of a clinical relationship, not the end of one.

Lactation

No lactation transfer concerns apply to diagnostic test strips. Women who are breastfeeding and want to test for a new pregnancy or UTI symptoms can use OTC tests without concern about effects on milk supply or infant safety. The clinical concern is the same as for any woman: a positive result requires follow-up.

Contraception

Stix is not a contraceptive platform. OPK-based timing, often called the "fertility awareness method" when used to avoid pregnancy, has a typical-use failure rate of approximately 24% compared to <1% for long-acting reversible contraception. Women should not rely on Stix OPKs as a contraceptive strategy without formal training in a recognized fertility awareness-based method and clinical counseling about efficacy.

Who This Is Right For vs. Who Needs a Clinician

The table below maps life stage and clinical scenario to the appropriate level of care.

| Life Stage | Scenario | Stix Appropriate? | What You Actually Need | |---|---|---|---| | Reproductive years, regular cycles | Confirming suspected pregnancy | Yes, as a first step | Clinical confirmation within 1-2 weeks | | Reproductive years, regular cycles | Timing intercourse, no fertility diagnosis | Yes, with limitations | OPK plus basal body temperature if desired | | Reproductive years, PCOS | Ovulation timing while TTC | No | Monitored cycle with transvaginal ultrasound | | Any age | First uncomplicated UTI with classic symptoms | Reasonable starting point | Telehealth or urgent care for prescription | | Any age | Second UTI within 6 months | No | Urine culture, sensitivity testing, clinical evaluation | | Perimenopause | Interpreting cycle changes or FSH test | No | Clinician evaluation; single FSH not diagnostic | | Post-menopause | UTI symptoms | No | Clinician to differentiate UTI from GSM | | Any age, prior ectopic | Positive pregnancy test | No, insufficient alone | Same-day serum hCG and clinical evaluation |

The Evidence Gap Women Deserve to Know About

Women have been historically underrepresented in medical device validation studies, and OTC diagnostic tests are no exception. The 2011 Clinical Chemistry study cited earlier evaluated pregnancy test brands primarily using laboratory hCG standards rather than real-world urine from diverse populations. Performance may differ based on urine concentration, timing of collection, medications affecting hCG or LH levels, and body composition.

A 2014 report in AJOG found that at-home pregnancy test errors were common and often related to user behavior rather than test failure, but the two are difficult to separate in practice. No published independent head-to-head comparison of Stix-branded tests against clinical laboratory hCG assays appears in peer-reviewed literature. Until that data exists, the performance claims on the Stix website reflect manufacturer-provided data, not independently replicated findings.

"Home diagnostic tests occupy an important but limited role in reproductive healthcare. They can initiate a conversation with a clinician, but they should never end one," notes Elena Vasquez, MD, WomanRx editorial board member and practicing OB-GYN. "The women I see most often harmed by OTC tests are those who used a negative result to feel reassured when their symptoms warranted a call."